# The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin

> **NCT03869268** · PHASE4 · COMPLETED · sponsor: **Sheffield Teaching Hospitals NHS Foundation Trust** · enrollment: 72 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Ticagrelor

## Key facts

- **NCT ID:** NCT03869268
- **Lead sponsor:** Sheffield Teaching Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-24
- **Primary completion:** 2021-12-10
- **Final completion:** 2023-02-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03869268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03869268, "The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03869268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*